Get the app
US › Healthcare

Soligenix Inc. (SNGX)

US · Healthcare · Biotechnology

$0.35-2.78%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Net profit
$-2.0M
EPS
$-0.12
EPS estimate
$-0.22

EPS came in at -0.12 against a street estimate of -0.22 — a beat of 45.5%.

Key statistics

Market cap
$7.7M
Forward P/E
12.3
P/B
1.23
Book value
$0.31
EPS (TTM)
$-0.79
52-week high
$1.76
52-week low
$0.28
50-day MA
$0.37
200-day MA
$0.73
Beta
2.00

Analyst view

Analysts rate Soligenix Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $1.38.

Shareholding

Insiders
4.59%
Institutions
6.72%

Largest institutional holders

FundStake
Citadel Advisors Llc0.96%
Jane Street Group LLC0.95%
XTX Topco Ltd0.72%
Geode Capital Management, LLC0.55%
Vanguard Capital Management, LLC0.37%
Virtu Financial LLC0.28%
Vanguard Fiduciary Trust Co0.25%
Northern Trust Corp0.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Soligenix Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.